{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"ISRCTN","place":["London, UK"]}],"indexed":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T15:44:19Z","timestamp":1746805459155,"version":"3.40.5"},"reference-count":0,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":["www.isrctn.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1186\/isrctn81968533","type":"dataset","created":{"date-parts":[[2012,12,5]],"date-time":"2012-12-05T20:22:08Z","timestamp":1354738928000},"update-policy":"https:\/\/doi.org\/10.1186\/isrctn_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase II sudy of cetuximab for the treatment of refractory or relapsed multiple myeloma Erbitux for Multiple MyelomA"],"prefix":"10.1186","author":[{"given":"Andreas","family":"Engert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","content-created":{"date-parts":[[2012,12,6]]},"container-title":["http:\/\/isrctn.org\/>"],"original-title":[],"deposited":{"date-parts":[[2015,6,12]],"date-time":"2015-06-12T10:12:37Z","timestamp":1434103957000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.isrctn.com\/ISRCTN81968533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,6]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1186\/isrctn81968533","relation":{},"subject":[],"published":{"date-parts":[[2012,12,6]]}}}